The Vanguard Group 13D and 13G filings for Zentalis Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-01-31 10:09 am Sale | 2024-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | The Vanguard Group | 3,271,240 4.590% | -1,341,467 (-29.08%) | Filing |
| 2024-11-12 6:00 pm Unchanged | 2024-09-30 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | The Vanguard Group | 4,612,707 6.480% | 0 (Unchanged) | Filing |
| 2024-11-04 2:16 pm Sale | 2024-09-30 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | The Vanguard Group | 4,612,707 6.480% | -737,751 (-13.79%) | Filing |
| 2024-02-13 5:17 pm Purchase | 2023-12-29 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | The Vanguard Group | 5,350,458 7.560% | 1,190,309 (+28.61%) | Filing |
| 2023-02-09 11:37 am Purchase | 2022-12-30 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | The Vanguard Group | 4,160,149 7.290% | 973,163 (+30.54%) | Filing |
| 2022-02-10 08:47 am Purchase | 2021-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | The Vanguard Group | 3,186,986 7.030% | 840,849 (+35.84%) | Filing |
| 2021-02-10 12:04 pm Purchase | 2020-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | The Vanguard Group | 2,346,137 5.780% | 2,346,137 (New Position) | Filing |